Expression levels of serum miR-25 in the patients with non-small cell lung cancer and its clinical significance
10.13602/j.cnki.jcls.2018.02.02
- VernacularTitle:非小细胞肺癌患者血清中miR-25的表达水平及筛查价值
- Author:
Jinsha ZHONG
1
;
Cheng WANG
;
Meng DING
;
Zhongpeng YIN
;
Chenyu ZHANG
;
Chunni ZHANG
Author Information
1. 南京大学医学院附属金陵医院
- Keywords:
non-small cell lung cancer;
serum;
miR-25;
biomarker
- From:
Chinese Journal of Clinical Laboratory Science
2018;36(2):86-89
- CountryChina
- Language:Chinese
-
Abstract:
Objective To determine the expression levels of serum miR-25 in the patients with non-small cell lung cancer (NSCLC),and evaluate its clinical significance in the screening of NSCLC.Methods Serum samples from 82 untreated NSCLC patients,including 4 with TNM satge Ⅰ,10 with TNM stage Ⅱ,11 with TNM stage Ⅲ,53 with TNM stage Ⅳ and 4 with unknown stage,and 82 healthy controls with matched age and gender were collected,and the levels of miR-25 in these samples were determined by quantitative reverse transcription PCR (qRT-PCR).The diagnostic value of miR-25 in NSCLC was evaluated by the receiver operating characteristic (ROC) curve.Results Serum miR-25 levels in NSCLC patients were significantly higher than that in healthy controls (0.017 ± 0.028 vs 0.004 ±0.004,t =4.098,P ＜0.01).The area under the ROC curve (AUGROC),sensitivity and specificity of miR-25 for the diagnosis of NSCLC were 0.818 (95％ CI:0.753-0.882),70.7％ and 80.7％,respectively.In addition,the AUCROC,sensitivity and specificity of serum miR-25 for the screening of stage Ⅰ/Ⅱ NSCLC were 0.852 (95％ CI:0.728-0.976),78.6％ and 87.8％,respectively.Logistic regression analysis showed that miR-25 was an independent risk factor of NSCLC (OR =10.84,95％ CI:5.07-23.19,P ＜ 0.01).Conclusion Serum miR-25 levels in NSCLC patients increase significantly,indicating that it may be a novel molecular biomarker for the screening of NSCLC.
